Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility.

Background: Progressive nonsteroidal anti-inflammatory drug (NSAID) dose reduction appears logical; however, there is no evidence-based medicine indicating that efficacy is maintained as dose is reduced.

Objective: To determine if NSAID dose can be reduced and pain relief and mobility can be maintained in dogs with osteoarthritis (OA).

Animals: Client-owned dogs (n = 59) with OA-associated impaired mobility and pain.